The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug ...

Regeneron and Alnylam are to research treatments for the chronic liver disease non-alcoholic steatohepatitis (NASH), under a new agreement. Alnylam specialises in treatments based around RNA ...

George J. Mailath, Do People Play Nash Equilibrium? Lessons from Evolutionary Game Theory, Journal of Economic Literature, Vol. 36, No. 3 (Sep., 1998), pp. 1347-1374 ...